Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Wong YJ, Nguyen MH. Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors-based direct-acting antivirals? Liver Int 2022;42:1207-1208. [PMID: 35220647 DOI: 10.1111/liv.15214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]

For:	Wong YJ, Nguyen MH. Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors-based direct-acting antivirals? Liver Int 2022;42:1207-1208. [PMID: 35220647 DOI: 10.1111/liv.15214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]

Number

Cited by Other Article(s)

Wong YJ, Kumar R, Kumar R, Tan J, Liu CH, Hui VW, Tan SS, Kao JH, Wong GL, Thurairajah PH. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry. J Gastroenterol Hepatol 2022;37:1642-1644. [PMID: 35723645 PMCID: PMC9543910 DOI: 10.1111/jgh.15918] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 06/16/2022] [Indexed: 12/12/2022]